|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
ES2175404T3
(es)
|
1996-05-10 |
2002-11-16 |
Icos Corp |
Derivados de carbolina.
|
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
|
WO1998058633A2
(en)
|
1997-06-23 |
1998-12-30 |
Queen's University At Kingston |
Microdose therapy of vascular conditions by no donors
|
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
|
WO2000056304A2
(en)
*
|
1999-03-24 |
2000-09-28 |
Harbor Branch Oceanographic Institution, Inc. |
Anti-inflammatory uses of manzamines
|
|
ES2187234A1
(es)
*
|
1999-04-30 |
2003-05-16 |
Lilly Icos Llc |
Forma de dosificacion oral para tratar la disfuncion sexual.
|
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
EA004872B1
(ru)
|
1999-08-03 |
2004-08-26 |
ЛИЛЛИ АЙКОС эЛ-эЛ-Си |
β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
|
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
|
AP2002002455A0
(en)
|
1999-10-11 |
2002-06-30 |
Pfizer |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
|
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
JP2004500425A
(ja)
|
2000-04-19 |
2004-01-08 |
リリー アイコス リミテッド ライアビリティ カンパニー |
パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
|
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
CA2411008C
(en)
*
|
2000-06-07 |
2006-04-11 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
EP1366049B1
(en)
|
2000-06-23 |
2006-06-21 |
Lilly Icos LLC |
Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives
|
|
ES2269408T3
(es)
*
|
2000-06-23 |
2007-04-01 |
Lilly Icos Llc |
Inhibidores de fosfodiesterasa especifica de gmp ciclico.
|
|
EP1313736B1
(en)
|
2000-06-26 |
2005-07-27 |
Lilly Icos LLC |
Condensed pyrazindione derivatives as inhibitors of pde5
|
|
CN1252055C
(zh)
*
|
2000-07-24 |
2006-04-19 |
拜尔农作物科学股份公司 |
联苯甲酰胺类化合物
|
|
EP1305313A1
(en)
*
|
2000-08-02 |
2003-05-02 |
Lilly Icos LLC |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6503894B1
(en)
*
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
WO2002028858A2
(en)
*
|
2000-10-02 |
2002-04-11 |
Lilly Icos Llc |
Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
|
|
ES2248399T3
(es)
|
2000-10-02 |
2006-03-16 |
Lilly Icos Llc |
Derivados de piridoindol condensado.
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
ATE337320T1
(de)
*
|
2000-11-06 |
2006-09-15 |
Lilly Icos Llc |
Indolderivate als pde5-inhibitoren
|
|
EP1383765B1
(en)
*
|
2001-04-25 |
2006-12-13 |
Lilly Icos LLC |
Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction
|
|
FR2824829B1
(fr)
*
|
2001-05-16 |
2005-06-03 |
Macef |
Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
|
|
WO2002098875A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Carboline derivatives as pde-5 inhibitors
|
|
WO2002098877A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
|
|
MXPA03011080A
(es)
*
|
2001-06-05 |
2004-07-08 |
Lilly Icos Llc |
Compuestos tetraciclicos como inhibidores de pde5.
|
|
WO2003000691A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Lilly Icos Llc |
Carboline derivatives as pdev inhibitors
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
|
CA2465893A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
PT1448562E
(pt)
*
|
2001-11-14 |
2007-08-31 |
Ortho Mcneil Pharm Inc |
Derivados da pirroloquinolona tetracíclica substituídos, úteis como inibidores da fosfodiesterase
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
CN1655820A
(zh)
*
|
2002-05-23 |
2005-08-17 |
辉瑞大药厂 |
Pde5抑制剂与ace抑制剂的药物组合
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
AU2003256539B2
(en)
*
|
2002-07-31 |
2010-03-04 |
Icos Corporation |
Modified pictet-spengler reaction and products prepared therefrom
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
WO2004054560A1
(en)
|
2002-12-13 |
2004-07-01 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
MXPA05010373A
(es)
|
2003-04-01 |
2005-12-05 |
Applied Research Systems |
Inhibidores de fosfodiesterasas en infertilidad.
|
|
EA008596B1
(ru)
|
2003-04-29 |
2007-06-29 |
Пфайзер Инк. |
5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
|
|
EA012279B1
(ru)
*
|
2003-05-22 |
2009-08-28 |
Никомед Гмбх |
Композиция, включающая ингибитор pde4 и ингибитор pde5
|
|
PL1644021T3
(pl)
*
|
2003-06-13 |
2013-01-31 |
Ironwood Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
|
|
ES2427166T3
(es)
|
2003-06-23 |
2013-10-29 |
Ono Pharmaceutical Co., Ltd. |
Compuesto heterocíclico tricíclico novedoso
|
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
US20060018970A1
(en)
*
|
2003-12-12 |
2006-01-26 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
CA2560538A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1737448A1
(en)
*
|
2004-03-22 |
2007-01-03 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
DE602005011784D1
(de)
|
2004-04-07 |
2009-01-29 |
Pfizer |
Pyrazoloä4,3-düpyrimidine
|
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
|
EP1776108A1
(en)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
EP1804582A4
(en)
*
|
2004-10-28 |
2009-12-09 |
Reddys Lab Ltd Dr |
POLYMORPH SHAPES OF TADALAFIL
|
|
TW200630348A
(en)
*
|
2004-11-02 |
2006-09-01 |
Teva Pharma |
Tadalafil crystal forms and processes for preparing them
|
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
WO2006068164A1
(ja)
|
2004-12-22 |
2006-06-29 |
Ono Pharmaceutical Co., Ltd. |
三環式化合物およびその用途
|
|
EP1851222A1
(en)
*
|
2005-02-25 |
2007-11-07 |
Teva Pharmaceutical Industries Ltd |
Process of synthesizing tadalafil
|
|
US7417044B2
(en)
*
|
2005-02-25 |
2008-08-26 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
|
CA2599458A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Process of purifying tadalafil
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
EP1812435A2
(en)
*
|
2005-04-12 |
2007-08-01 |
Teva Pharmaceutical Industries Ltd |
Preparation of tadalafil intermediates
|
|
NZ561746A
(en)
|
2005-04-19 |
2011-09-30 |
Nycomed Gmbh |
Roflumilast for the treatment of pulmonary hypertension
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
BRPI0609225A2
(pt)
|
2005-05-12 |
2010-03-09 |
Pfizer |
formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
AU2006275702A1
(en)
*
|
2005-07-29 |
2007-02-08 |
Concert Pharmaceuticals Inc. |
Novel pharmaceutical compounds
|
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
|
ES2646326T3
(es)
|
2005-08-03 |
2017-12-13 |
Sprout Pharmaceuticals, Inc. |
Uso de flibanserina en el tratamiento de la obesidad
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US20070104792A1
(en)
*
|
2005-09-13 |
2007-05-10 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
|
ES3012497T3
(en)
|
2005-10-12 |
2025-04-09 |
Besins Healthcare Lu Sarl |
Improved testosterone gel and method of use
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
CA2626134C
(en)
|
2005-10-29 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
|
WO2007056457A2
(en)
|
2005-11-09 |
2007-05-18 |
Combinatorx, Incorporated |
Methods, compositions, and kits for the treatment of medical conditions
|
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP1991212A1
(en)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2004644A1
(en)
*
|
2006-03-24 |
2008-12-24 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
|
JP2009541443A
(ja)
|
2006-06-30 |
2009-11-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
尿失禁及び関連疾患の治療のためのフリバンセリン
|
|
KR101140110B1
(ko)
*
|
2006-07-07 |
2012-06-04 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
|
|
EP2046292B1
(en)
|
2006-07-21 |
2010-03-03 |
Novartis AG |
Formulations for benzimidazolyl pyridyl ethers
|
|
EP2054041A2
(en)
|
2006-08-14 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Formulations of flibanserin and method for manufacturing the same
|
|
IL197129A
(en)
|
2006-08-25 |
2014-08-31 |
Boehringer Ingelheim Int |
Controlled release system and method for production
|
|
AR062501A1
(es)
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
EP2068872A1
(en)
*
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
AU2007299920A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2101777B1
(en)
|
2006-12-12 |
2015-05-20 |
Gilead Sciences, Inc. |
Composition for treating a pulmonary hypertension
|
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
|
CN101674728A
(zh)
*
|
2007-02-12 |
2010-03-17 |
Dmi生物科学公司 |
降低曲马多的副作用
|
|
CN101657101B
(zh)
*
|
2007-02-12 |
2013-12-11 |
Dmi生物科学公司 |
并存早泄和勃起功能障碍的治疗
|
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
KR20100012867A
(ko)
*
|
2007-04-25 |
2010-02-08 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타다라필을 포함하는 고체 제형
|
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
KR20100027170A
(ko)
*
|
2007-06-29 |
2010-03-10 |
랜박시 래보러터리스 리미티드 |
테트라사이클릭 화합물의 중간체의 제조 방법
|
|
EP2033962A1
(en)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetracyclic indolopyridines as EG5 inhibitors
|
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
|
EP2107059A1
(en)
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion of tryptophan into ß-carboline derivatives
|
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
EP2181997A1
(en)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
A process for the preparation of tadalafil
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
JP6074142B2
(ja)
|
2009-02-26 |
2017-02-01 |
タール ファーマシューティカルズ，インコーポレイテッド |
医薬化合物の結晶化
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
CN102970965A
(zh)
|
2010-04-05 |
2013-03-13 |
Sk化学公司 |
含有pde5抑制剂的减少皮肤皱纹的合成物
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
NZ610012A
(en)
|
2010-10-15 |
2015-05-29 |
Gilead Sciences Inc |
Compositions and methods of treating pulmonary hypertension
|
|
JP5816704B2
(ja)
|
2011-02-10 |
2015-11-18 |
インテルキム、ソシエダッド アノニマ |
テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
|
|
RU2013141446A
(ru)
|
2011-02-10 |
2015-03-20 |
Синтон Бв |
Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
|
|
EP2672959A1
(en)
|
2011-02-10 |
2013-12-18 |
Synthon BV |
Granulated composition comprising tadalafil and a disintegrant
|
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
|
EP2535049A1
(en)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil for the treatment of dementia
|
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2013109230A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical compositions comprising tadalafil
|
|
WO2013109225A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical tablet formulations comprising ceftibuten
|
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
CN104168895B
(zh)
|
2012-02-28 |
2020-02-21 |
首尔制药株式会社 |
包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
|
|
WO2014055801A1
(en)
|
2012-10-05 |
2014-04-10 |
Henkin Robert I |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
|
US9750743B2
(en)
|
2012-12-04 |
2017-09-05 |
Aribio Inc. |
Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
EP2938343B1
(en)
|
2012-12-21 |
2018-09-12 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating calcific aortic valve stenosis
|
|
CN105102457A
(zh)
|
2013-02-21 |
2015-11-25 |
阿德弗里奥药品有限责任公司 |
{4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
|
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
|
ES2776353T3
(es)
|
2013-07-17 |
2020-07-30 |
Univ Columbia |
Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
|
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
US10598672B2
(en)
|
2014-02-18 |
2020-03-24 |
Cyrano Therapeutics, Inc. |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
|
MX2016014384A
(es)
|
2014-06-23 |
2017-01-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
|
|
EP2962684A1
(en)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
WO2016001143A1
(en)
|
2014-06-30 |
2016-01-07 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
EA035390B1
(ru)
|
2014-07-23 |
2020-06-05 |
КРКА, д.д., НОВО МЕСТО |
Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
ES2774048T3
(es)
*
|
2015-06-26 |
2020-07-16 |
Chongqing Dikang Erle Pharma Co Ltd |
Nuevo inhibidor de la fosfodiesterasa de tipo 5 y su aplicación
|
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
|
EP4620525A3
(en)
|
2016-12-14 |
2025-12-03 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
|
WO2020210707A1
(en)
|
2019-04-10 |
2020-10-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for gender-dependent treatment of cardiovascular dysfunction
|
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
|
CN114158266A
(zh)
|
2019-07-15 |
2022-03-08 |
生物实验萨纽斯药物有限公司 |
化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途
|
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
JP7606530B2
(ja)
|
2020-03-24 |
2024-12-25 |
シラノ セラピューティクス， インコーポレイテッド |
コロナウイルス感染症による化学感覚機能障害の治療
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
KR20240117491A
(ko)
|
2023-01-25 |
2024-08-01 |
주식회사 아리바이오 |
포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
|
|
AU2024220563A1
(en)
|
2023-02-16 |
2025-08-14 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|
|
CN116715667A
(zh)
*
|
2023-06-20 |
2023-09-08 |
常州制药厂有限公司 |
一种他达拉非新晶型b及其制备方法
|
|
EP4684777A1
(en)
|
2024-07-24 |
2026-01-28 |
Adalvo Limited |
A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione
|